ArticleScientific reports2025
MT1JP/miR-103a-3p induce pyroptosis and regulate the tumor immune microenvironment in gastric cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding the molecular mechanisms of pyroptosis and its therapeutic development prospects.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Immune checkpoint blockade (ICB) has made great progress in treating cancer, regulating the tumor immune microenvironment can improve the efficacy of ICB and has become a major focus. Pyroptosis, as a new form of cell death, has been reported in a few diseases to activate cellular immune responses due to the release of inflammatory factors. This may offer a new approach for regulating the tumor immune microenvironment. MT1JP plays an important role in gastric cancer, but its mechanism of pyroptosis and immunity is unclear. Bioinformatics analysis combined with qRT-PCR revealed the expression levels of MT1JP and miR-103a-3p in GC cells and tissues, and their interactions were revealed by dual-luciferase assay and rescue experiment. The effects of MT1JP on GC cell proliferation, invasion, and migration were assessed by CCK-8, EdU, Colony formation, Wound healing, and Transwell. Western blot, IHC, IF, and ELISA were used to assess the effects of MT1JP/miR-103a-3p in GC cell pyroptosis and immunity. MT1JP expression was downregulated and miR-103a-3p was upregulated in GC cells and tissues, the expression of MPDZ was downregulated in AGS and MKN-45. Overexpression of MT1JP inhibited GC cell proliferation, invasion, and migration. MT1JP directly targets and inhibits miR-103a-3p. MT1JP/miR-103a-3p induced the expression of pyroptosis-related proteins (GSDMD, NLRP3, Caspase1) and inflammatory factors (IL-1β, IL-18), activated the immune pathway Sting/IFN-β, and downregulated PD-L1. Based on bioinformatics analysis and preliminary exploration in this study, MPDZ may be a potential downstream target of miR-103a-3p. MT1JP/miR-103a-3p can induce pyroptosis, activate the immune response, and then inhibited the growth of gastric cancer, possibly acting through MPDZ. This explored a new anti-cancer method to regulate the tumor immune microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.